171 related articles for article (PubMed ID: 8793400)
21. Pseudomonas aeruginosa and the airways disease of cystic fibrosis.
Hata JS; Fick RB
Clin Chest Med; 1988 Dec; 9(4):679-89. PubMed ID: 3148384
[TBL] [Abstract][Full Text] [Related]
22. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Griese M; Müller I; Reinhardt D
Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.
White L; Mirrani G; Grover M; Rollason J; Malin A; Suntharalingam J
Respir Med; 2012 Mar; 106(3):356-60. PubMed ID: 22204744
[TBL] [Abstract][Full Text] [Related]
24. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.
Gladman G; Connor PJ; Williams RF; David TJ
Arch Dis Child; 1992 Feb; 67(2):192-5. PubMed ID: 1371914
[TBL] [Abstract][Full Text] [Related]
25. Bulgarian cystic fibrosis Pseudomonas aeruginosa isolates: antimicrobial susceptibility and neuraminidase-encoding gene distribution.
Strateva T; Petrova G; Perenovska P; Mitov I
J Med Microbiol; 2009 May; 58(Pt 5):690-692. PubMed ID: 19369536
[No Abstract] [Full Text] [Related]
26. Nebulised anti-pseudomonal antibiotics for cystic fibrosis.
Ryan G; Mukhopadhyay S; Singh M
Cochrane Database Syst Rev; 2000; (2):CD001021. PubMed ID: 10796732
[TBL] [Abstract][Full Text] [Related]
27. Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Ang JY; Abdel-Haq N; Zhu F; Thabit AK; Nicolau DP; Satlin MJ; van Duin D
Antimicrob Agents Chemother; 2016 Oct; 60(10):5627-30. PubMed ID: 27664282
[TBL] [Abstract][Full Text] [Related]
28. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
[TBL] [Abstract][Full Text] [Related]
29. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
30. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Millar BC; Malnarcic CM; McCaughan J; Moore JE
Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
[No Abstract] [Full Text] [Related]
31. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.
Cheng K; Smyth RL; Govan JR; Doherty C; Winstanley C; Denning N; Heaf DP; van Saene H; Hart CA
Lancet; 1996 Sep; 348(9028):639-42. PubMed ID: 8782753
[TBL] [Abstract][Full Text] [Related]
32. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
[TBL] [Abstract][Full Text] [Related]
33. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
34. Molecular epidemiology of chronic pulmonary colonisation by Pseudomonas aeruginosa in cystic fibrosis.
Boukadida J; De Montalembert M; Lenoir G; Scheinmann P; Véron M; Berche P
J Med Microbiol; 1993 Jan; 38(1):29-33. PubMed ID: 8418289
[TBL] [Abstract][Full Text] [Related]
35. Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis.
Sherrard LJ; Tai AS; Wee BA; Ramsay KA; Kidd TJ; Ben Zakour NL; Whiley DM; Beatson SA; Bell SC
PLoS One; 2017; 12(3):e0172179. PubMed ID: 28273168
[TBL] [Abstract][Full Text] [Related]
36. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
37. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Mouton JW; den Hollander JG; Horrevorts AM
J Antimicrob Chemother; 1993 Jun; 31(6):919-26. PubMed ID: 8360129
[TBL] [Abstract][Full Text] [Related]
38. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
Zabner R; Quinn JP
Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
